Kenneth Hoberman's most recent trade in Nuvectis Pharma Inc was a trade of 30,000 Common Stock done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nuvectis Pharma Inc | Kenneth Hoberman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 30,000 | 133,140 | - | 0 | Common Stock | |
| TG Therapeutics Inc | Kenneth Hoberman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 14,718 | 279,653 (0%) | 0% | 0 | Common Stock | |
| TG Therapeutics Inc | Kenneth Hoberman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2024 | 22,250 | 264,935 (0%) | 0% | 0 | Common Stock | |
| Nuvectis Pharma Inc | Kenneth Hoberman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 103,140 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Kenneth Hoberman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 18,000 | 73,140 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Kenneth Hoberman | Director | Purchase of securities on an exchange or from another person at price $ 17.40 per share. | 12 May 2022 | 6,000 | 55,140 | - | 17.4 | 104,400 | Common Stock |
| Nuvectis Pharma Inc | Kenneth Hoberman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 15,000 | 15,000 | - | - | Stock Options (right to buy) |